Beijing Foyou PharmaLTD Resultados de beneficios anteriores
Pasado controles de criterios 3/6
Beijing Foyou PharmaLTD has been growing earnings at an average annual rate of 17.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.3% per year. Beijing Foyou PharmaLTD's return on equity is 14.8%, and it has net margins of 14.9%.
Información clave
17.6%
Tasa de crecimiento de los beneficios
10.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 10.9% |
| Tasa de crecimiento de los ingresos | 7.3% |
| Rentabilidad financiera | 14.8% |
| Margen neto | 14.9% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastos
Cómo gana y gasta dinero Beijing Foyou PharmaLTD. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 3,424 | 510 | 1,345 | 430 |
| 30 Jun 24 | 3,365 | 529 | 1,282 | 406 |
| 31 Mar 24 | 3,323 | 508 | 1,314 | 364 |
| 31 Dec 23 | 3,340 | 489 | 1,350 | 353 |
| 30 Sep 23 | 3,337 | 488 | 1,428 | 288 |
| 30 Jun 23 | 3,327 | 483 | 1,481 | 270 |
| 31 Mar 23 | 3,312 | 467 | 1,496 | 259 |
| 31 Dec 22 | 3,240 | 439 | 1,494 | 238 |
| 30 Sep 22 | 3,160 | 385 | 1,484 | 228 |
| 30 Jun 22 | 3,059 | 357 | 1,461 | 204 |
| 31 Mar 22 | 2,975 | 340 | 1,446 | 191 |
| 31 Dec 21 | 2,838 | 314 | 1,401 | 177 |
| 31 Dec 20 | 2,535 | 263 | 1,342 | 138 |
| 31 Dec 19 | 2,425 | 219 | 1,398 | 169 |
| 31 Dec 18 | 2,020 | 200 | 1,094 | 140 |
Ingresos de calidad: 601089 has a high level of non-cash earnings.
Margen de beneficios creciente: 601089's current net profit margins (14.9%) are higher than last year (14.6%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 601089's earnings have grown by 17.6% per year over the past 5 years.
Acelerando crecimiento: 601089's earnings growth over the past year (4.6%) is below its 5-year average (17.6% per year).
Beneficios vs. Industria: 601089 earnings growth over the past year (4.6%) exceeded the Pharmaceuticals industry -1.2%.
Rentabilidad financiera
Alta ROE: 601089's Return on Equity (14.8%) is considered low.